In 2019, Dicot began a research collaboration with Pelvipharm, a world-leading contract research organization (CRO) specializing in advanced animal models for evaluating sexual dysfunctions. Pelvipharm has produced a large number of scientific articles in the field and has participated in preclinical testing of several drug candidates developed for erectile dysfunction and premature ejaculation. They have collaborated with more than 60 customers, including Pfizer when conducting preclinical tests in connection with the development of Viagra.
The purpose of the research collaboration is to study the effect of LIB-01 in Pelvipharm's defined and carefully validated animal models and to identify the mechanism of action with which LIB-01 exerts its effect.
In March 2020, the first of several studies within this collaboration was initiated to clarify LIB-01's effect and future area of use.